Relmada Therapeutics, Inc.
RLMD · NASDAQ
Bulios Fair Price
$3.52
15.4% downside
Current Price
$4.16
According to Bulios Fair Price, RLMD is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Relmada Therapeutics, Inc. (RLMD) is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of central nervous system disorders and other neurologically focused health conditions. Their research and development programs are aimed at discovering and developing new drug therapies for mood disorders, pain, and other neurological diseases. Among their main products are drugs based on new pharmacological mechanisms, which have the potential to provide new therapeutic options for patients with these health conditions. Relmada Therapeutics, Inc. aims to bring innovative treatment approaches and improve the quality of life for patients suffering from neurological disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Sergio Traversa
Employees
17
Headquarters
Coral Gables
Upcoming events
Earnings
Upcoming earnings report